日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷

Ask the Experts: Hib (Haemophilus influenzae type b)

Results (29)

Haemophilus influenzae?is a bacteria that has encapsulated (typeable) or unencapsulated (nontypeable) strains. Encapsulated strains express one of six antigenically capsular polysaccharides (types a, b, c, d, e, or f). Historically, type b (Hib) was the most common type to cause invasive disease, particularly in young children.?H. influenzae?colonizes the upper respiratory tract of humans and is transmitted person-to-person by inhalation of respiratory droplets or by direct contact with respiratory tract secretions.

Encapsulated?H. influenzae?nontype b strains, particularly type a, can cause invasive disease similar to Hib disease. Nontypeable strains also can cause invasive disease but more commonly cause mucosal infections such as otitis media, conjunctivitis, and sinusitis. Vaccines are only available for?H. influenzae?type b; Hib vaccines do not protect against disease caused by any other?H. influenzae?strains.

Last reviewed: January 21, 2025

Before 1985, Hib was the leading cause of bacterial meningitis and a common cause of other invasive diseases (such as epiglottitis, pneumonia, septic arthritis, cellulitis, purulent pericarditis, and bacteremia) among U.S. children younger than 5 years of age. An estimated 20,000 cases of invasive Hib disease occurred in this age group each year. Meningitis occurred in approximately two-thirds of children with invasive Hib disease; 15%–30% of survivors had hearing impairment or severe permanent neurologic sequelae. Approximately 3%–6% of all cases were fatal.

Following the licensure of conjugate Hib vaccines in 1987 and 1989, the incidence of Hib disease fell dramatically. During 1989 – 2000, the annual incidence of invasive Hib disease among children younger than 5 years of age decreased by 99%, to less than one case per 100,000 children. Since 2000, the average annual incidence rate of invasive Hib disease among children younger than 5 years of age in the United States remained below the Healthy People 2020 goal of 0.27/100,000 children.

Only 17 confirmed cases of invasive Hib disease among children younger than 5 years were reported in the United States in 2022. The majority of Hib disease in the United States occurs among unimmunized and underimmunized infants and children (those who have an incomplete primary series or are lacking a booster dose) and among infants too young to have completed the primary immunization series.

Last reviewed: January 21, 2025

People with certain immunocompromising conditions are considered at increased risk for invasive Hib disease. These conditions include functional or anatomic asplenia, HIV infection, immunoglobulin (antibody) deficiency including immunoglobulin G2 subclass deficiency, early component complement deficiency, use of a complement inhibitor (such as eculizumab [Soliris], ravulizumab [Ultomiris], or similar), receipt of a hematopoietic stem cell transplant, or receipt of chemotherapy or radiation therapy for treatment of cancer.

Last reviewed: January 21, 2025

Haemophilus influenzae?type b is a polysaccharide-encapsulated bacteria that causes a variety of invasive diseases, such as meningitis, epiglottitis, and pneumonia. Influenza is a virus that causes the disease influenza.

Historical note:?Haemophilus influenzae?was first isolated in 1889 from the sputum of a patient who died of (viral) influenza disease, and the isolated organism (then called the Pfeiffer bacillus) was incorrectly assumed to have caused the patient’s illness.?Haemophilus influenzae?received its name in 1920, to acknowledge its historical association with influenza illness. The viral cause of influenza was not discovered until 1933.

Last reviewed: January 21, 2025

The most recent comprehensive Advisory Committee on Immunization Practices (ACIP) recommendations for Hib vaccination were published in 2014 and are available on the CDC website at?www.cdc.gov/acip-recs/hcp/vaccine-specific/hib.html. An ACIP update, adding Vaxelis (DTaP-IPV-Hib-HepB, MSP Company) as a preferred Hib-containing option for vaccination of American Indian/Alaska Native children was published in September 2024 and is also available at the link above. Guidance for Hib vaccination is also provided in the annual childhood immunization schedule, available at?www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html.

Last reviewed: January 21, 2025

Three monovalent Hib vaccines are available in the United States: PedvaxHIB (PRP-OMP, Merck), ActHIB (PRP-T, Sanofi) and Hiberix (PRP-T, GSK). These vaccines are composed of Hib purified polyribosylribitol phosphate (PRP) capsular polysaccharide chemically bound (conjugated) to a protein to enhance the quality of the immune response to PRP. All three vaccines are approved for infants in a 3- or 4-dose series (depending on brand).

Two combination vaccines containing Hib are currently available in the United States: Pentacel (DTaP-IPV/Hib, Sanofi) and Vaxelis (DTaP-IPV-Hib-HepB, MSP Company). Pentacel is licensed for use in children younger than age 5 years and contains Hib conjugate, DTaP, and inactivated polio vaccines; it is approved as a 4-dose series for infants at age 2, 4, 6, and 15 through 18 months, but it is not approved for use as the DTaP/IPV booster dose recommended at age 4 to 6 years. Vaxelis (DTaP-IPV-Hib-HepB) is licensed for use in children younger than age 5 years and is FDA-approved and recommended by CDC as a 3-dose primary series of Hib for infants at age 2, 4, and 6 months. Vaxelis is not approved for use as a Hib booster (4th) dose. Vaxelis contains the same PRP-OMP Hib antigen as PedvaxHIB, but in a reduced amount; like PedvaxHIB, it is an ACIP-preferred option for administration to American Indian and Alaska Native infants (who are at increased risk of early-onset invasive Hib disease) because it induces protective antibody levels after the first dose.

Last reviewed: January 21, 2025

ACIP recommends routine administration of a conjugate Hib vaccine series for all infants beginning at age 2 months. Infants 2 through 6 months of age should receive a 3-dose series of ActHIB, Hiberix, Pentacel, or Vaxelis, or a 2-dose series of PedvaxHIB. The first dose can be administered as early as age 6 weeks, but not earlier. Hib-containing vaccine should not be given before 6 weeks of age. Doses given before 12 months of age should be separated by at least 4 weeks. A booster dose (which will be dose 3 or 4 depending on vaccine type used in primary series) of any Hib-containing vaccine is recommended at age 12 through 15 months and at least 8 weeks after the most recent Hib dose. Vaxelis is recommended only for the primary Hib series and is not recommended for use as a booster (4th) dose. A different Hib-containing vaccine licensed for a booster dose should be used.

Medically stable preterm infants should be vaccinated beginning at age 2 months according to the schedule recommended for other infants, on the basis of chronological age. For special situations in children, refer to the current CDC recommended immunization schedule Hib notes: www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html.

Last reviewed: January 21, 2025

Yes, for the primary series. If either ActHIB (PRP-T), Hiberix (PRP-T), Vaxelis (DTaP-IPV-Hib-HepB), or Pentacel (DTaP-IPV/Hib) is used for a routine primary series dose, a complete routine primary series consists of three doses. PedvaxHIB (PRP-OMP) requires a 2-dose primary series, but if administering a mixed-product primary series including only one dose of PedvaxHIB, a total of 3 doses is needed to complete the primary series.

Vaxelis is not recommended for use as a Hib booster (4th) dose. A different Hib-containing vaccine licensed for the booster dose should be used. If Vaxelis is inadvertently given as the booster dose, the dose does not need to be repeated with another Hib-containing vaccine, if the proper spacing of prior doses is maintained.

Last reviewed: January 21, 2025

Healthcare providers should refer to the catch-up schedule published as part of the CDC Recommended Child and Adolescent Immunization Schedule (available at?www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-catch-up.html). The catch-up schedule will help determine the number of additional doses needed and the minimum intervals between doses. However, if a healthy child receives a single dose of Hib vaccine at age 15 months or older, he or she does not need any further doses regardless of the number of doses received before age 15 months. Some high-risk children between the age of 15 months and 59 months will be recommended for two doses of Hib vaccine based on previous history of incomplete vaccination; these special situations are reviewed in the Hib notes section of the schedule: www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html.

Last reviewed: January 21, 2025

No. If a healthy child receives a dose of Hib vaccine at 15 months of age or older, he or she does not need any further doses regardless of the number of doses received before 15 months of age.

Last reviewed: January 21, 2025

If the child received a primary series (2 or 3 doses, depending upon the product) of Hib vaccine in the first year of life, then the final (booster) dose of the series may be given as early as 12 months, provided at least 2 months have passed since the last dose. An unvaccinated 12–14-month-old child should receive one dose as a primary series, and a booster dose 2 months later. Unvaccinated healthy children 15–59 months of age need only a single dose of any licensed conjugate Hib vaccine. Some high-risk children 15–59 months of age are recommended for two doses of Hib vaccine based on previous history of incomplete vaccination; these special situations are reviewed in the Hib notes section of the schedule: www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html.

Last reviewed: January 21, 2025

Yes. All children less than 5 years old need at least one dose of Hib vaccine on or after the first birthday. The last dose should be separated from the previous dose by at least 8 weeks.

Last reviewed: January 21, 2025

Use of DTaP-IPV solution as the diluent for the Hib component is specifically written both on the Pentacel box AND on the DTaP-IPV vial label. The DTaP-IPV component will count as valid doses of DTaP and IPV vaccines, but you should take measures to prevent this error in the future. You cannot mix the Hib component with sterile water. ActHib must ONLY be reconstituted with either the DTaP-IPV solution supplied with Pentacel, or with a specific ActHib saline diluent. If you have a vial of lyophilized ActHib but neither diluent, you must contact the manufacturer (Sanofi) and obtain ActHib diluent.

Last reviewed: January 21, 2025

ACIP does not recommend routine Hib vaccination of healthy children 60 months of age or older, even if they have no prior history of Hib vaccination.

Last reviewed: January 21, 2025

Limited data suggest that Hib vaccine given before 6 weeks of age may induce immunologic tolerance to Hib antigen and reduce the response to subsequent doses. As a result, Hib vaccine should not be given earlier than 6 weeks of age. However, if a dose was administered before 6 weeks of age, it should NOT be counted as part of the Hib series. A full series of 3 or 4 doses, depending on the product used, should be started at 2 months of age as usual. No special protocol or testing is recommended for children who received a dose of Hib vaccine before 6 weeks of age.

Last reviewed: January 21, 2025

Hib vaccine is not routinely recommended for healthy adults 19 years and older, even if the person did not receive Hib vaccine as a child. However, ACIP recommends that one dose of Hib vaccine should be administered to individuals who have anatomical or functional asplenia or sickle cell disease or are undergoing elective splenectomy if they have not previously received Hib vaccine. Hib vaccine should be administered 14 or more days before splenectomy if possible. Recipients of a hematopoietic stem cell transplant should be vaccinated with a 3-dose series of Hib vaccine 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses. Hib vaccine is not recommended for adults with HIV infection since their risk for Hib disease is low.

Last reviewed: January 21, 2025

When elective splenectomy is planned, vaccination with pneumococcal, meningococcal, and Hib vaccines should precede surgery by at least 2 weeks, if possible. If vaccines are not administered before surgery, they should be administered as soon as the person’s condition stabilizes after surgery.

Last reviewed: January 21, 2025

Pneumococcal conjugate vaccine (PCV), Haemophilus influenzae type b (Hib) vaccine, MenACWY, and meningococcal B vaccine should be given at least 14 days before a scheduled splenectomy, if possible. This is done so the patient is protected from these diseases before the spleen is removed; however, doses given during the 14 days before surgery also can be counted as valid. If the doses cannot be given prior to the splenectomy, they should be given as soon as the patient’s condition has stabilized after surgery. If PCV20 or PCV21 is given, pneumococcal polysaccharide vaccine (PPSV23) is not needed; if PCV15 is given, administer a dose of PPSV23 at least 8 weeks after the dose of PCV15 if the patient is age 2 years or older.

Last reviewed: November 15, 2024

Since the patient is asplenic, the second dose of the primary series of MenACWY should be given at least 8 weeks after the first dose. He will need a dose of MenACWY every 5 years for the rest of his life. The 3-dose series of MenB (whether Trumenba [Pfizer] or Bexsero [GSK]) should be completed. The first booster dose of MenB will be due one year after completion of the primary series and subsequent booster doses are recommended every 2–3 years for the rest of his life. The same MenB vaccine should be used for all doses in the series, including booster doses. People who receive Trumenba brand MenB vaccine have an option to receive MenABCWY (Penbraya, Pfizer) when both MenACWY and MenB vaccines are due at the same visit, as long as doses of Penbraya are spread out by at least 6 months. The patient has already received one dose of PCV20, in accordance with pneumococcal vaccination recommendations for immunocompromised adults younger than age 50, so no further doses are needed. Based on the patient’s age, only one dose of Hib vaccine is recommended, so no further doses are needed. The patient should receive influenza vaccine annually.

Any of these vaccines can be given at the same appointment.

Last reviewed: November 15, 2024

You are interpreting the recommendations correctly, and age is an important factor in this issue. The recommendation for Hib vaccination for asplenia applies to people of all ages. Only children ages 12 through 59 months are subject to the recommendation for Hib vaccination for immunoglobulin deficiency or early component complement deficiency or use of a complement inhibitor (such as eculizumab [Soliris], or a related product).

Last reviewed: January 21, 2025

Yes. If different brands of Hib vaccine are given at 2 and 4 months of age then the child should receive a third primary dose of either vaccine at 6 months of age. A 2-dose primary schedule (that is, doses at age 2 and 4 months) is only appropriate when both doses are PedvaxHIB.

Last reviewed: January 21, 2025

Hib invasive disease does not always result in development of protective antibody levels. Children younger than 24 months of age who develop invasive Hib disease should be considered susceptible and should receive Hib vaccine. Vaccination of these children should start as soon as possible during the convalescent phase of the illness. A complete series as recommended for the child’s age should be administered.

Last reviewed: January 21, 2025

Hib meningitis incidence historically peaked at a younger age (4–6 months) among AI/AN infants than among other U.S. infant populations (6–7 months). ACIP has made a preferential recommendation for vaccination with a primary series of PedvaxHIB (PRP-OMP, Merck) or Vaxelis (DTaP-IPV-Hib-HepB, MSP Company) for AI/AN infants. PedvaxHIB and Vaxelis (which also contains PRP-OMP as its Hib component) both produce a protective antibody response after the first dose.

Last reviewed: January 21, 2025

All Hib-containing vaccines should be administered by the intramuscular route.

Last reviewed: January 21, 2025

The third dose of Vaxelis (DTaP-IPV-Hib-HepB, MSP Company) administered at age 5 months (less than 24 weeks of age) is not considered a valid dose of the HepB component, because the last dose of HepB vaccine should be given at 24 weeks of age or older. The child will need an additional dose of HepB vaccine at age 24 weeks or older, and at least 4 weeks after the inadvertent dose of Vaxelis. The DTaP, IPV, and Hib components of the Vaxelis dose erroneously administered at age 5 months are considered valid doses and do not need to be repeated, as long as there was a minimum 4-week interval between the second and third doses of these three components.

Last reviewed: January 21, 2025

Hib vaccination is contraindicated for individuals known to have experienced a severe allergic reaction (anaphylaxis) to a vaccine component or following a prior dose. Hib-containing vaccines are contraindicated for children younger than 6 weeks of age because of the potential for development of immunologic tolerance. The PedvaxHIB vial stopper contains dry natural rubber which could produce an allergic reaction in children with severe allergy to latex.

Vaccination should be delayed for children with moderate or severe acute illnesses. Minor illnesses, such as a mild upper respiratory infection are not a reason to delay vaccination.

Contraindications and precautions for the use of Pentacel (DTaP-IPV/Hib) and Vaxelis (DTaP-IPV-Hib-HepB) are the same as those for their individual component vaccines.

Last reviewed: January 21, 2025

There is an extremely rare risk of an unpredictable, serious allergic reaction (anaphylaxis) following administration of any vaccine. Most people have no side effects from Hib vaccination. Some experience fever or a mild reaction at the injection site, including redness, warmth, tenderness, or swelling. These side effects resolve without treatment within a day or two after vaccination.

All serious adverse events that occur after receipt of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS) (https://vaers.hhs.gov).

Last reviewed: January 21, 2025

Hib vaccine should be maintained at refrigerator temperature between 2°C and 8°C (36°F and 46°F). Manufacturer package inserts contain additional information and can be found at? www.immunize.org/official-guidance/fda/pkg-inserts/. For complete information on best practices and recommendations please refer to CDC’s?Vaccine Storage and Handling Toolkit?available at this website: www.cdc.gov/vaccines/hcp/storage-handling/index.html.

Last reviewed: January 21, 2025

CDC published its current guidance for chemoprophylaxis of close contacts of a patient with invasive Hib disease on page 10 of its February 28, 2014, MMWR, “Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)”, available at: www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.

According to the MMWR, secondary cases of Hib disease (illness occurring within 60 days of contact with a patient) occur but are rare. Secondary attack rates are higher among household contacts younger than 48 months (2.1%), especially those younger than 12 months (6%) and younger than 24 months (3%). Data are conflicting on the risk for secondary illness among childcare contacts, but it is thought to be lower than among household contacts. Rifampin is recommended for chemoprophylaxis because it achieves high concentrations in respiratory secretions and eradicates nasopharyngeal carriage in more than 95% of carriers.

Index patients who are treated with an antibiotic other than cefotaxime or ceftriaxone and are younger than 2 years of age should receive rifampin prior to hospital discharge. Because cefotaxime and ceftriaxone eradicate Hib colonization, prophylaxis is not needed for patients treated with either of these antibiotics.

Rifampin chemoprophylaxis is recommended for all household contacts in households with members younger than 4 years who are not fully vaccinated, households with a child younger than 12 months who has not completed the primary Hib series, or households with a contact who is an immunocompromised child regardless of that child’s vaccination status.

Rifampin chemoprophylaxis is recommended in childcare settings when two or more cases of invasive Hib disease have occurred within 60 days and unimmunized or underimmunized children attend the facility. When prophylaxis is indicated, it should be prescribed for all attendees, regardless of age or vaccine status, and for childcare providers. Refer to the current AAP Red Book chapter on?Haemophilus influenzae?infections for more information on this issue and consult with local or state public health for guidance.

There are no guidelines for control measures around cases of invasive non-type b?H. influenzae?disease at this time. Chemoprophylaxis is not recommended for contacts of persons with invasive disease caused by non-type b?H. influenzae?although a small number of secondary cases have been documented. Information about secondary cases of non-type b H. influenzae invasive disease is available in this 2023 MMWR, entitled “Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae — 10 U.S. Jurisdictions, 2011–2018”, available at www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7215a2-H.pdf.

Last reviewed: January 21, 2025

This page was updated on .

日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷
不卡影院免费观看| 色哟哟国产精品免费观看| 亚洲国产毛片aaaaa无费看| 色婷婷综合中文久久一本| 日韩欧美一二三| 日本欧洲一区二区| av成人免费在线| 亚洲精品国产一区二区三区四区在线| 亚洲成人一区二区在线观看| 国产.精品.日韩.另类.中文.在线.播放| 东方欧美亚洲色图在线| 日韩av二区在线播放| 久久综合久久综合久久综合| 一区在线播放视频| 亚洲综合av网| 日韩一级在线观看| 亚洲第一成人在线| 久久精品噜噜噜成人88aⅴ| 色综合久久久久网| 国产欧美一区二区精品性| 久久久精品天堂| 中文字幕乱码亚洲精品一区| 亚洲成人免费视频| 欧美色手机在线观看| 中文字幕乱码久久午夜不卡| www.欧美日韩| 粉嫩欧美一区二区三区高清影视| 欧美极品少妇xxxxⅹ高跟鞋| 精品99一区二区| 亚洲免费av观看| 国产精品久久久久久久久免费桃花| 91欧美激情一区二区三区成人| 精品视频全国免费看| 久久成人麻豆午夜电影| 一区二区三区在线视频观看| 欧美亚一区二区| 99国产一区二区三精品乱码| 91亚洲男人天堂| 精品福利视频一区二区三区| 久久综合狠狠综合久久综合88| 国产欧美日韩一区二区三区在线观看| 国产欧美精品国产国产专区| 成人av中文字幕| 精品一区二区免费看| 亚洲mv在线观看| 91精品国产综合久久蜜臀| 精品视频色一区| 欧美视频一区二区三区| 欧美国产视频在线| 亚洲欧美激情视频在线观看一区二区三区| 国产成人午夜高潮毛片| 国产欧美精品区一区二区三区| 久久aⅴ国产欧美74aaa| 国产麻豆精品一区二区| 一区二区三区在线看| 欧美一二区视频| 色婷婷亚洲婷婷| 性久久久久久久久| 亚洲自拍都市欧美小说| 国产激情精品久久久第一区二区| 日韩在线卡一卡二| 亚洲欧美综合网| 亚洲欧美在线另类| 久久久久亚洲蜜桃| 国产一区二区在线免费观看| 日本午夜一区二区| 欧美日本一道本在线视频| 大桥未久av一区二区三区中文| 国产一区二区三区四区五区入口| 国产精品久久久久久久久搜平片| 久久亚洲精品国产精品紫薇| 欧美一区二区在线免费观看| 欧美裸体一区二区三区| 国产午夜精品一区二区三区四区| 亚洲欧美日韩成人高清在线一区| 伊人色综合久久天天| 亚洲一区二区三区不卡国产欧美| 国产精品看片你懂得| 久久99国产精品免费| 91视频在线观看| 国产最新精品精品你懂的| 欧美激情综合网| 亚洲高清久久久| 亚洲成a人v欧美综合天堂下载| 国内精品久久久久影院薰衣草| 日本精品一级二级| 欧美激情综合在线| 国产精品国产精品国产专区不片| 人人爽香蕉精品| 制服.丝袜.亚洲.另类.中文| 国产99久久久精品| 国产乱子轮精品视频| 日日夜夜精品视频天天综合网| 91精品国产免费久久综合| ...av二区三区久久精品| 日韩一本二本av| 91麻豆精品国产无毒不卡在线观看| 亚洲一区二区三区影院| 中文字幕视频一区二区三区久| 欧美国产精品一区二区三区| 99视频一区二区| 欧美日韩免费一区二区三区视频| 日韩精品自拍偷拍| 日韩你懂的在线播放| 国产精品电影一区二区三区| 久久亚洲精品国产精品紫薇| 亚洲蜜桃精久久久久久久| 欧美唯美清纯偷拍| 欧美三级在线视频| 国产日韩影视精品| 久久午夜色播影院免费高清| 国产精品国产三级国产专播品爱网| 久久久亚洲精品石原莉奈| 六月丁香综合在线视频| 亚洲午夜激情网页| 日韩精品亚洲一区二区三区免费| 国产激情91久久精品导航| 久久视频一区二区| 在线免费观看日本欧美| 午夜精品免费在线观看| 国产不卡一区视频| 在线观看亚洲精品| 欧美性色欧美a在线播放| 亚洲欧洲精品一区二区三区不卡| caoporen国产精品视频| 色综合天天综合给合国产| 国产精品久久久久久久久久免费看| 国产精品一级在线| 欧美日韩成人综合| 欧美精品乱码久久久久久按摩| 裸体健美xxxx欧美裸体表演| 国产精品激情偷乱一区二区∴| 国产乱理伦片在线观看夜一区| 亚洲一区免费在线观看| 国产一区二区在线观看免费| 欧美欧美午夜aⅴ在线观看| 奇米精品一区二区三区在线观看一| 国模一区二区三区白浆| 精品国产91久久久久久久妲己| 色综合久久中文综合久久牛| 美腿丝袜一区二区三区| 韩国av一区二区三区四区| 国产午夜精品久久久久久久| 7777精品伊人久久久大香线蕉完整版| 色综合久久88色综合天天免费| 不卡的av电影在线观看| 欧美www视频| 日韩一级成人av| 亚洲一区二区成人在线观看| 亚洲一区二区影院| 自拍偷拍欧美激情| 日韩一区二区在线观看视频播放| 亚洲综合成人在线| 日韩国产欧美在线视频| 久久电影国产免费久久电影| 亚洲欧美日韩国产综合在线| 成人不卡免费av| 在线免费观看日本欧美| 中文字幕乱码一区二区免费| 亚洲国产日产av| 国产亚洲成aⅴ人片在线观看| 天堂久久一区二区三区| 色偷偷久久人人79超碰人人澡| 精品国产成人在线影院| 久久精品国产久精国产爱| 亚洲国产日韩精品| 国产精品污www在线观看| 中文字幕电影一区| 综合网在线视频| 国产日韩欧美精品一区| av网站一区二区三区| 在线中文字幕一区二区| 精品国产凹凸成av人导航| 综合色中文字幕| 国产91丝袜在线观看| 国产成人免费视频精品含羞草妖精| 中文字幕亚洲综合久久菠萝蜜| 国产精品网曝门| 久久久久久久av麻豆果冻| 欧美做爰猛烈大尺度电影无法无天| 美脚の诱脚舐め脚责91| 精品国产乱码久久久久久蜜臀| 国产亚洲精品精华液| www.日韩av| 大美女一区二区三区| 在线观看国产精品网站| 日韩精品乱码av一区二区| 午夜久久久久久久久久一区二区| 亚洲精品国产第一综合99久久| 一本到一区二区三区| 免费不卡在线观看| 欧美性一二三区| 麻豆精品一二三| 精品嫩草影院久久| 日av在线不卡| 亚洲aⅴ怡春院| 久久综合狠狠综合久久激情| 亚洲精品成人天堂一二三| 91一区二区在线观看| 亚洲不卡av一区二区三区|